Published in Br J Cancer on November 01, 1995
Management of malignant teratoma: does referral to a specialist unit matter? Lancet (1993) 3.73
Centralised treatment, entry to trials and survival. Br J Cancer (1994) 3.46
How accurate are Scottish cancer registration data? Br J Cancer (1994) 1.85
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Management of malignant teratoma: does referral to a specialist unit matter? Lancet (1993) 3.73
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res (1989) 2.71
Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci U S A (1984) 2.69
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Chromatin structure and gene activity: the role of nonhistone chromosomal proteins. CRC Crit Rev Biochem (1982) 2.31
Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish Melanoma Group. Lancet (1992) 2.31
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Therapy for testicular cancer in Central and Eastern Europe. Lancet (1990) 2.08
Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis (1997) 2.05
Medical audit, cancer registration, and survival in ovarian cancer. Lancet (1991) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol (2000) 1.69
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Changes in testicular cancer in Scotland. Eur J Cancer Clin Oncol (1987) 1.58
The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clin Radiol (1997) 1.56
Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clin Oncol (R Coll Radiol) (1998) 1.56
Recurrent aphthae: treatment with vitamin B12, folic acid, and iron. Br Med J (1975) 1.56
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol (2002) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Carboplatin or cisplatin? Lancet (1988) 1.53
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol (1995) 1.53
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer (1991) 1.52
Late spontaneous anterior dislocation of an intraocular lens (IOL) with the capsular bag. Eye (Lond) (2005) 1.52
The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer (1992) 1.49
Collagen corneal shields. Surv Ophthalmol (2002) 1.49
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy (2011) 1.45
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol (2012) 1.44
Antiemetic therapy--where do we go from here? Ann Oncol (1993) 1.43
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol (1983) 1.42
Nipple aspirate fluid in relation to breast cancer. Breast (1999) 1.41
The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol (1986) 1.41
Chemotherapy of advanced malignant teratomas. Br J Cancer (1980) 1.40
Acquired resistance to prolonged treatment with intravenous "Arvin" (ancrod). Br J Clin Pract (1977) 1.39
Scottish hospital morbidity data. 2. An attempt to improve the standard of diagnostic entries and records in a medical unit. Health Bull (Edinb) (1976) 1.38
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Scottish hospital morbidity data. 3. Some suggestions for improvement of the accuracy. Health Bull (Edinb) (1976) 1.38
Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer (1993) 1.36
Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol (1997) 1.35
Fluoroquinolones: place in ocular therapy. Drugs (2001) 1.34
Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. Br J Cancer (1979) 1.32
Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol (2007) 1.29
Retinoids: present role and future potential. Br J Cancer (1999) 1.28
Phase I and pharmacokinetic study of rhizoxin. Cancer Res (1992) 1.26
Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs. Br Med J (Clin Res Ed) (1985) 1.25
Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res (1987) 1.24
Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol (1999) 1.22
The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer (1996) 1.20
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer (1993) 1.20
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol (2008) 1.19
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. Br J Cancer (1979) 1.19
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res (1986) 1.19
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol (1996) 1.18
Drug resistance reversal--are we getting closer? Eur J Cancer (2003) 1.18
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res (1993) 1.18
Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev (2000) 1.17
On the receiving end--II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol (1983) 1.17
Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer (1995) 1.16
Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer (2001) 1.16
P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer (1990) 1.15
Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil. Br J Cancer (1989) 1.14
Chart for visual acuity screening. Br J Ophthalmol (1989) 1.14
VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer (1980) 1.13
Non-random position of the A-T rich DNA sequences in early embryos of Drosophila virilis. Chromosoma (1981) 1.11
Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol (1984) 1.11
Gemcitabine: current status of phase I and II trials. J Clin Oncol (1994) 1.11
Cross-resistance to cytotoxic drugs in human glioma cell lines in culture. Br J Cancer (1984) 1.10
Pneumocystis pneumonia. Br Med J (Clin Res Ed) (1983) 1.10
Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil. Br J Cancer (1986) 1.10
The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol (1990) 1.10
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer (1997) 1.09
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev (2010) 1.09
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer (1989) 1.08
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol (1997) 1.07
From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther (2009) 1.06
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. Br J Cancer (2012) 1.06
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer (1999) 1.06
Basaloid carcinoma of the prostate gland: histogenesis and review of the literature. Histopathology (1992) 1.06
Monoclonal antibodies against a specific nonhistone chromosomal protein of Drosophila associated with active genes. J Cell Biol (1981) 1.05
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst (1995) 1.05
Primary pulmonary osteosarcoma: case report and molecular analysis. Cancer (2001) 1.05
Distribution studies on polytene chromosomes using antibodies directed against hnRNP. J Cell Biol (1981) 1.04
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. Br J Surg (1984) 1.04